116 related articles for article (PubMed ID: 12430568)
21. [Therapeutic impact of alpha interferon in chronic myelogenous leukaemia].
Tolo-Diebkilé A; Koffi KG; Sawadogo GD; Ndiaye FS; Nanho DC; Sékongo YM; Kouakou B; Méité N; Ayemou R; Sanogo I
Mali Med; 2010; 25(1):22-7. PubMed ID: 21436004
[TBL] [Abstract][Full Text] [Related]
22. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
[TBL] [Abstract][Full Text] [Related]
23. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Saussele S; Krauss MP; Hehlmann R; Lauseker M; Proetel U; Kalmanti L; Hanfstein B; Fabarius A; Kraemer D; Berdel WE; Bentz M; Staib P; de Wit M; Wernli M; Zettl F; Hebart HF; Hahn M; Heymanns J; Schmidt-Wolf I; Schmitz N; Eckart MJ; Gassmann W; Bartholomäus A; Pezzutto A; Leibundgut EO; Heim D; Krause SW; Burchert A; Hofmann WK; Hasford J; Hochhaus A; Pfirrmann M; Müller MC;
Blood; 2015 Jul; 126(1):42-9. PubMed ID: 25918346
[TBL] [Abstract][Full Text] [Related]
24. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
Kalmanti L; Saussele S; Lauseker M; Proetel U; Müller MC; Hanfstein B; Schreiber A; Fabarius A; Pfirrmann M; Schnittger S; Dengler J; Falge C; Kanz L; Neubauer A; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Krause SW; Heim D; Nerl C; Hossfeld DK; Kolb HJ; Hochhaus A; Hasford J; Hehlmann R; ;
Ann Hematol; 2014 Jan; 93(1):71-80. PubMed ID: 24162333
[TBL] [Abstract][Full Text] [Related]
25. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).
Thielen N; van der Holt B; Cornelissen JJ; Verhoef GE; Gussinklo T; Biemond BJ; Daenen SM; Deenik W; van Marwijk Kooy R; Petersen E; Smit WM; Valk PJ; Ossenkoppele GJ; Janssen JJ
Eur J Cancer; 2013 Oct; 49(15):3242-6. PubMed ID: 23876833
[TBL] [Abstract][Full Text] [Related]
26. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
Castagnetti F; Testoni N; Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A; Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
J Clin Oncol; 2010 Jun; 28(16):2748-54. PubMed ID: 20439635
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
28. Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan.
Nagai T; Takeuchi J; Dobashi N; Kanakura Y; Taniguchi S; Ezaki K; Nakaseko C; Hiraoka A; Okada M; Miyazaki Y; Motoji T; Higashihara M; Tsukamoto N; Kiyoi H; Nakao S; Shinagawa K; Ohno R; Naoe T; Ohnishi K; Usui N
Int J Hematol; 2010 Jul; 92(1):111-7. PubMed ID: 20577839
[TBL] [Abstract][Full Text] [Related]
29. CML clonal evolution with resistance to single agent imatinib therapy.
Swords R; Quinn J; Fay M; O'Donnell R; Goldman J; Murphy PT
Clin Lab Haematol; 2005 Oct; 27(5):347-9. PubMed ID: 16178920
[TBL] [Abstract][Full Text] [Related]
30. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
[TBL] [Abstract][Full Text] [Related]
31. Imatinib therapy for chronic myeloid leukemia: where do we go now?
Cortes JE
J Clin Oncol; 2008 Jul; 26(20):3308-9. PubMed ID: 18519950
[No Abstract] [Full Text] [Related]
32. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
33. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.
White DL; Dang P; Engler J; Frede A; Zrim S; Osborn M; Saunders VA; Manley PW; Hughes TP
J Clin Oncol; 2010 Jun; 28(16):2761-7. PubMed ID: 20421539
[TBL] [Abstract][Full Text] [Related]
34. Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia.
Bernardini K; Lanthaler AJ; Buratti T; Mitterer M
Am J Hematol; 2006 Mar; 81(3):224-5. PubMed ID: 16493606
[No Abstract] [Full Text] [Related]
35. The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group.
Guilhot F; Guerci A; Fiere D; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Rochant H; Najman A; Nicolini F; Colombat P; Abgrall JF; Ifrah N; Brière J; Bauters F; Navarro M; Morice P; Bordessoule D; Vilque JP; Desablens B; Tertian G; Blanc M; Chastang C; Tanzer J
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S29-31. PubMed ID: 8769697
[No Abstract] [Full Text] [Related]
36. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
37. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Advani AS; Tiu R; Saunthararajah Y; Maciejewski J; Copelan EA; Sobecks R; Sekeres MA; Bates J; Rush ML; Tripp B; Salvado A; Noon E; Howard M; Jin T; Hsi E; Egorin MJ; Lim K; Cotta CV; Price C; Kalaycio M
Leuk Res; 2010 Dec; 34(12):1622-6. PubMed ID: 20427086
[TBL] [Abstract][Full Text] [Related]
38. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.
Reed SD; Anstrom KJ; Li Y; Schulman KA
Pharmacoeconomics; 2008; 26(5):435-46. PubMed ID: 18429659
[TBL] [Abstract][Full Text] [Related]
39. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
40. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Hehlmann R; Lauseker M; Jung-Munkwitz S; Leitner A; Müller MC; Pletsch N; Proetel U; Haferlach C; Schlegelberger B; Balleisen L; Hänel M; Pfirrmann M; Krause SW; Nerl C; Pralle H; Gratwohl A; Hossfeld DK; Hasford J; Hochhaus A; Saussele S
J Clin Oncol; 2011 Apr; 29(12):1634-42. PubMed ID: 21422420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
